Payment overview · 2025
General Payments
$520.81
26 reported records · 12 companies
Healthcare provider profile · identity verified
Wilfredo Corredera, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAKE PLACID, FL · NPI 1891743365
Verified facts
What the public records show
CMS Open Payments records show Wilfredo Corredera, M.D. received $520.81 in general payments during 2025 across 26 reported records.
Corcept Therapeutics accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $139.63 | 26.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.64 | 17.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.82 | 9.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $44.13 | 8.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.12 | 8.1% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $34.63 | 6.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.22 | 4.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.36 | 4.3% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $20.50 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.00 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.03 | 3.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.73 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $520.81 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $139.63 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.64 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.82 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $44.13 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.12 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $34.63 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 912 | 264 |
| Atorvastatin Calcium | Atorvastatin Calcium | 908 | 269 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 752 | 234 |
| Levothyroxine Sodium | Levothyroxine Sodium | 609 | 181 |
| Metformin Hcl | Metformin Hcl | 503 | 157 |
| Metoprolol Succinate | Metoprolol Succinate | 486 | 146 |
| Lisinopril | Lisinopril | 405 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 357 | 123 |
| Telmisartan | Telmisartan | 356 | 106 |
| Simvastatin | Simvastatin | 325 | 94 |
| Losartan Potassium | Losartan Potassium | 320 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 81 |
| Omeprazole | Omeprazole | 246 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 210 | 61 |
| Potassium Chloride | Potassium Chloride | 201 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 60 |
| Carvedilol | Carvedilol | 199 | 62 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 191 | 62 |
| Gabapentin | Gabapentin | 179 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 56 |
| Furosemide | Furosemide | 164 | 68 |
| Ezetimibe | Ezetimibe | 158 | 46 |
| Eliquis | Apixaban | 153 | 52 |
| Allopurinol | Allopurinol | 147 | 44 |
| Montelukast Sodium | Montelukast Sodium | 142 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 139 | 41 |
| Glipizide | Glipizide | 136 | 40 |
| Alprazolam | Alprazolam | 135 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 34 |
| Ozempic | Semaglutide | 127 | 28 |
| Finasteride | Finasteride | 115 | 38 |
| Atenolol | Atenolol | 108 | 30 |
| Sertraline Hcl | Sertraline Hcl | 100 | 33 |
| Tramadol Hcl | Tramadol Hcl | 95 | 31 |
| Donepezil Hcl | Donepezil Hcl | 89 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 38 |
| Jardiance | Empagliflozin | 86 | 26 |
| Cefadroxil | Cefadroxil | 82 | 67 |
| Torsemide | Torsemide | 82 | 25 |
| Lorazepam | Lorazepam | 81 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 38 |
| Tresiba Flextouch U-200 | Insulin Degludec | 79 | 23 |
| Famotidine | Famotidine | 77 | 29 |
| Pregabalin | Pregabalin | 77 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 18 |
| Xarelto | Rivaroxaban | 74 | 22 |
| Alendronate Sodium | Alendronate Sodium | 67 | 20 |
| Clonazepam | Clonazepam | 67 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 20 |
| Myrbetriq | Mirabegron | 65 | 21 |
| Naproxen | Naproxen | 65 | 37 |
| Memantine Hcl | Memantine Hcl | 64 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 45 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 17 |
| Meloxicam | Meloxicam | 57 | 18 |
| Prednisone | Prednisone | 57 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 20 |
| Fenofibrate | Fenofibrate | 54 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 16 |
| Temazepam | Temazepam | 54 | 16 |
| Farxiga | Dapagliflozin Propanediol | 53 | 14 |
| Trazodone Hcl | Trazodone Hcl | 51 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 16 |
| Glimepiride | Glimepiride | 46 | 14 |
| Mirtazapine | Mirtazapine | 46 | 17 |
| Spironolactone | Spironolactone | 46 | 15 |
| Valsartan | Valsartan | 46 | 15 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Trulicity | Dulaglutide | 44 | 14 |
| Synthroid | Levothyroxine Sodium | 43 | 16 |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 11 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 17 |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Zaleplon | Zaleplon | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520.81 · 26 records | Corcept Therapeutics | ACTIV.A.C., AIRSUPRA, Cologuard Collection Kit, JARDIANCE, KEVEYIS, Kerendia, Korlym, LEQVIO, Leqembi, Ozempic, REXULTI, Rybelsus, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error